The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Risk factors for aspiration pneumonia related to postoperative chemoradiotherapy for high-risk head and neck cancer: A supplementary analysis of a phase II/III JCOG1008 trial.
 
Tomoya Yokota
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Eisai; Lilly Japan; Merck; MSD; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Japan Agency for Medical Research and Development; Merck; MSD; Pharmaceuticals and Medical Devices Agency; Rakuten Medical
Research Funding - Abbvie (Inst); Ascent Pharmahealth (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai/Roche (Inst); Daiichi Sankyo/UCB Japan (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Japan Agency for Medical Research and Development; Kyowa Kirin International (Inst); Lilly Japan (Inst); Merck (Inst); MSD (Inst); Nanobiotix (Inst); Novartis (Inst); Syneos Health (Inst)
 
Naomi Kiyota
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Eisai; Lilly Japan; Merck Serono; MSD; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - Adlai Nortye; Ono Pharmaceutical; Shift Zero
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); Ono Pharmaceutical (Inst)
 
Makoto Tahara
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Genmab; GlaxoSmithKline; Janssen; Lilly; Merck KGaA; MSD; Nanobiotix; Ono Pharmaceutical; Pfizer; Rakuten Medical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Nanobiotix (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Rakuten Medical (Inst)
 
Takeshi Kodaira
Honoraria - AstraZeneca Japan; Hitachi; Janssen; Merck; MSD; Otsuka; Sapporo Medical University; Shizuoka Cancer Center; Tohoku University
Research Funding - Japan Ministry of Health, Labour and Welfare; National Cancer for Research and Development Funds, Japan
 
Hiroshi Nishino
No Relationships to Disclose
 
Ayako Nakanome
No Relationships to Disclose
 
Yuji Hirayama
No Relationships to Disclose
 
Naoki Nishio
No Relationships to Disclose
 
Akira Ohkoshi
No Relationships to Disclose
 
Kaoru Tanaka
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Eisai; Kyowa Kirin Co., Ltd.; Merck Serono; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Nobuya Monden
No Relationships to Disclose
 
Masato Nagaoka
No Relationships to Disclose
 
Shujiro Minami
No Relationships to Disclose
 
Akira Seto
No Relationships to Disclose
 
Satoshi Kano
No Relationships to Disclose
 
Takayuki Taruya
No Relationships to Disclose
 
Go Omura
No Relationships to Disclose
 
Junki Mizusawa
Employment - Pfizer (I)
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Eisai (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Keita Sasaki
No Relationships to Disclose